Oncosil Medical Limited reported preliminary consolidated and company earnings results for the year ended June 30, 2013. For the period, on consolidated basis, the company's net loss was AUD 879,168 or 0.70 cents per basic and diluted share on revenues of AUD 87,711 against net loss of AUD 430,970 or 0.44 cents per basic and diluted share on revenues of AUD 163,615 a year ago. Net cash used in operating activities was AUD 471,908 against AUD 305,783 a year ago. Purchase of plant and equipment was AUD 3,722 against AUD 2,400 a year ago.

For the period, the company's net loss was AUD 775,998 against AUD 430,970 a year ago.